Addison's Disease News and Research

Latest Addison's Disease News and Research

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

AddisonsDisease.Net celebrates ten years of service

Teleplexus, Inc. is pleased to announce the ten-year anniversary of AddisonsDisease.Net, its premier Addison's disease support resource. Born by design on New Year's Day in 2002, AddisonsDisease.Net began service on this day which is seen around the world as a time of renewal and optimism.

2 Jan 2012

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Cortisol hormone controls bile acid recycling process

Nature sees to it that we do not have "too much choler" in our body. A delicately equilibrated regulation system ensures that there is always exactly the right amount of bile in the gallbladder. When we are hungry, our body releases a hormone called cortisol, which is a glucocorticoid. Hepatic cells receive this hormone signal through their cortisol receptors and respond by filling the gallbladder with bile in preparation of the imminent food intake.

8 Jul 2011

Acura, Pfizer receive FDA approval for OXECTA Tablets to manage severe pain

Pfizer Inc. and Acura Pharmaceuticals Inc. announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM Tablets CII.

20 Jun 2011

Cypress receives FDA approval for ZUTRIPRO, REZIRA NDA to treat cough and common cold

Cypress Pharmaceutical announced today that the Food and Drug Administration (FDA) approved a new drug application (NDA) for ZUTRIPRO Oral Solution (CIII) and REZIRA Oral Solution.

14 Jun 2011

Addison's patients with low cortisol levels more likely to get infections

Two new studies presented at the European Congress of Endocrinology in Rotterdam show the possible dangers facing patients with Addison's disease are higher than previously thought.

2 May 2011

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

Patients with chronic conditions need support to re-enter employment

A new study has identified a significant shortfall in patients with life-long but treatable conditions re-entering employment. The research is being presented at the annual Society for Endocrinology BES meeting in Manchester.

17 Mar 2010

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

Vitiligo gene linked to other autoimmune diseases

In a study appearing in the March 22 New England Journal of Medicine, scientists supported by the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered a connection between a specific gene and the inflammatory skin condition vitiligo, as well as a possible host of autoimmune diseases.

11 Apr 2007

Researchers discover vitiligo gene

In a study appearing in the March 22 edition of The New England Journal of Medicine, researchers at St George's, University of London, the University of Colorado at Denver and Health Sciences Center (UCDHSC) and the Barbara Davis Center for Childhood Diabetes have discovered a connection between a gene and the chronic skin condition vitiligo, as well as a possible link to an array of other autoimmune diseases.

22 Mar 2007

Sniff of male sweat kick starts female hormones

According to a new study all a healthy heterosexual woman needs to give their hormone levels a kick start is the smell of a man's sweat.

8 Feb 2007

Nematode hormone discovery may aid fight against parasitic disease

New research at UT Southwestern Medical Center shows that on a biochemical level, hormone-like molecules in tiny worms called nematodes work similarly to the way in which certain hormones work in humans - findings that one day may help eradicate worm infections that afflict a third of the world's population.

9 Mar 2006

Serum sodium level is a major predictor of a poor prognosis for heart failure patients

Research presented today at the American College of Cardiology's Scientific Sessions in Orlando pinpoints a major marker of a poor prognosis for heart failure, hyponatremia, or a lower than normal concentration of serum or blood sodium.

7 Mar 2005

Asthma or allergies in an expectant mother may increase the likelihood that her child will exhibit symptoms of autism

This association between a mother's asthma and allergies and a child's autism has not been reported in the medical literature previously, says Dr. Croen, and requires replication in further studies.

7 Feb 2005